-
Mashup Score: 1Combination Therapy Improves Quality of Life in Advanced Stomach Cancer, Esophageal Cancer - 7 month(s) ago
Combining an immune checkpoint inhibitor with standard chemotherapy improved quality of life for patients with advanced stomach cancer or esophageal cancer compared to chemotherapy alone, according to recent findings published in The Journal of Clinical Oncology.
Source: news.feinberg.northwestern.eduCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Esophageal Cancer | Did You Know? - 7 month(s) ago
Did you know that more than 49,000 people are living with esophageal cancer in the United States? Learn about the two main subtypes for this cancer and their…
Source: www.youtube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Did you know more than 49,000 people are living with #EsophagealCancer in the United States? Watch our ‘Did You Know?’ video to learn about this cancer: https://t.co/WSES3iwRNK
-
-
Mashup Score: 0Development and validation of a nomogram to predict cardiac death after radiotherapy for esophageal cancer - 7 month(s) ago
Radiotherapy for esophageal cancer (EC) increased cardiovascular toxicity and mortality in patient d. We developed and validated a nomogram that accurately predicted cardiac mortality variables in EC…
Source: onlinelibrary.wiley.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In an #OA study, researchers aim to develop a nomogram model that can predict the 5- and 10-year risk of cardiac death in patients receiving #EsophagealCancer radiotherapy. More in Cancer Innovation ➡️ https://t.co/OmHOwH7o37 https://t.co/iYsaUx3Z2T
-
-
Mashup Score: 4Addition of First-Line Regorafenib to Nivolumab and Chemotherapy in Metastatic Esophageal Cancer - The ASCO Post - 7 month(s) ago
In a single-institution phase II study reported in The Lancet Oncology, Cytryn et al found that the combination of regorafenib, nivolumab, and FOLFOX (fluorouracil, leucovorin, and oxaliplatin) showed activity as a first-line treatment regimen for patients with HER2-negative metastatic esophagogastric adenocarcinoma. In the investigator-initiated trial, 39 patients enrolled between February 2021 and May 2022 at Memorial Sloan Kettering Cancer Center received FOLFOX (fluorouracil at 400 mg/m² bolus
Source: ascopost.comCategories: Latest Headlines, Oncologists2Tweet-
RT @ASCOPost: Novel Triplet for Metastatic Esophageal Cancer: Study Results https://t.co/LaK7kC3Ip0 #esocsm #esophagealcancer #oncology
-
Novel Triplet for Metastatic Esophageal Cancer: Study Results https://t.co/LaK7kC3Ip0 #esocsm #esophagealcancer #oncology
-
-
Mashup Score: 0Quality of Life With Nivolumab Plus Chemotherapy in Advanced Gastric/GEJ Cancer or Esophageal Adenocarcinoma - The ASCO Post - 7 month(s) ago
As reported in the Journal of Clinical Oncology, Markus Moehler, MD, and colleagues found that in the phase III CheckMate 649 trial, the addition of nivolumab to chemotherapy was associated with generally better patient-reported health-related quality of life outcomes in patients with advanced non–HER2-positive (HER2-negative or unknown HER2 status) gastric/gastroesophageal junction cancer or esophageal adenocarcinoma. The trial supported the April 2021 approval of nivolumab in combination with fluoropyrim
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Advanced Gastric and Esophageal Cancer: Quality of Life With Immunochemotherapy https://t.co/2sybdrJhwi #stcsm #esocsm #gastriccancer #esophagealcancer #GEJcancer #oncology #immunotherapy
-
-
Mashup Score: 0
Six-month weight loss up to the time of diagnosis and symptom distress were evaluated to determine their effects on quality of life for patients with esophageal cancer treated with surgery and chemotherapy.
Source: www.oncologynurseadvisor.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Survivors of #esophagealCancer who experience a larger loss of body mass between 6 months prior to diagnosis and the time of diagnosis and who have greater symptom burden have worse QOL. Published in @sciencedirect. https://t.co/FXjKLdvKYc
-
-
Mashup Score: 0Addition of First-Line Regorafenib to Nivolumab and Chemotherapy in Metastatic Esophageal Cancer - The ASCO Post - 7 month(s) ago
In a single-institution phase II study reported in The Lancet Oncology, Cytryn et al found that the combination of regorafenib, nivolumab, and FOLFOX (fluorouracil, leucovorin, and oxaliplatin) showed activity as a first-line treatment regimen for patients with HER2-negative metastatic esophagogastric adenocarcinoma. In the investigator-initiated trial, 39 patients enrolled between February 2021 and May 2022 at Memorial Sloan Kettering Cancer Center received FOLFOX (fluorouracil at 400 mg/m² bolus
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Addition of First-Line Regorafenib to Nivolumab and Chemotherapy in Metastatic Esophageal Cancer https://t.co/LaK7kC3azs #esocsm #esophagealcancer #oncology
-
-
Mashup Score: 0Incidence of Esophageal Cancer on the Decline in the US - 8 month(s) ago
The incidence of esophageal cancer in the United States declined from 1975 to 2018, according to researchers.
Source: www.cancertherapyadvisor.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The incidence of #esophagealCancer in the United States declined from 1975 to 2018. Published in @JAMANetworkOpen. https://t.co/dhNUUxEopg
-
-
Mashup Score: 0
An AI tool can accurately forecast esophageal and stomach cancer risk well in advance, reshaping the landscape of cancer prevention.
Source: www.oncology-central.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🔬 An AI tool has been found to accurately predict #EsophagealCancer & #StomachCancer risk years before diagnosis. Read more here >>> https://t.co/fuTFZAin1V #ArtificalIntelligence #CancerPrevention
-
-
Mashup Score: 0Esophageal Cancer Rates Have Declined Since 2004 - 8 month(s) ago
An analysis of the incidence of esophageal cancer in the United States between 1975 and 2018 found that rates increased from 1975 before decreasing overall since 2004. This study was published in JAMA Network Open. The study utilized data from the Surveillance, Epidemiology, and End Results (SEER) registries from January 1975 through December 2019 for patients with a diagnosis of esophageal cancer, including its 2 primary histologic subtypes: squamous cell carcinoma of the esophagus (SCE) and adenocarcinom
Source: www.docwirenews.comCategories: Latest Headlines, Partners & KOLsTweet-
An analysis found that esophageal cancer rates have declined in the United States since 2004. #gioncology #esophagealcancer https://t.co/OFGqLPC42j
-
An analysis found that esophageal cancer rates have declined in the United States since 2004. #gioncology #esophagealcancer https://t.co/9Ni2WJSQmd https://t.co/gIGKwn3pfH
-
“We have a win-win for patients.” Combining a PD-1 checkpoint inhibitor w/ chemotherapy improved quality of life for patients with advanced #stomachcancer or #esophagealcancer, according to findings from @LurieCancer’s David Cella, PhD, in @JCO_ASCO https://t.co/ZO5LmKQgyl #QoL